In a nutshell This trial was carried out to analyze whether the length of time without treatment and the length of time without active disease influences the survival of patients with advanced breast cancer (ABC) spread to the bone taking palbociclib (Ibrance) plus hormonal therapy (HT). The authors concluded...
Read More
In a nutshell This trial was carried out to assess the effectiveness and safety of veliparib (ABT-888) in combination with carboplatin (Paraplatin) and paclitaxel (Taxol) in BRCA-mutated advanced breast cancer (BC). The authors found that the addition of veliparib to platinum-based chemotherapy resulted...
Read More
In a nutshell This study investigated the effectiveness and safety of atezolizumab (Tecentriq) as an addition to chemotherapy before surgery for patients with early-stage triple-negative breast cancer (TNBC). The data showed that the combination is effective in improving treatment response in these patients. Some background...
Read More
In a nutshell This trial is aiming to examine the effectiveness of ipatasertib in combination with atezolizumab (Tecentriq) and paclitaxel (Taxol) for the treatment of advanced triple-negative breast cancer (TNBC) that cannot be surgically removed. The main outcomes to be measured in this trial is survival without progression of the disease and...
Read More
In a nutshell The study evaluated the contribution of chemotherapy on cancer-related cognitive impairment (CRCI) reported by women with early breast cancer. The authors found that chemotherapy added to hormonal therapy caused early and short-term CRCI in such patients, compared to hormonal therapy alone. Some background CRCI refers to problems in...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of atezolizumab plus nab-paclitaxel in unresectable, locally advanced or metastatic triple-negative breast cancer. This study concluded that this combination had a benefit in patients with PD-L1 immune cell positive...
Read MoreIn a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...
Read More
In a nutshell This study is examining the effectiveness of biological drug sacituzumab govitecan (IMMU-132) compared to standard treatments for patients with hormone receptor-positive metastatic breast cancer. The main outcomes that will be measured are cancer responsiveness to the drug and survival of patients without the cancer growing. This trial...
Read MoreIn a nutshell This study aimed to investigate the combination of letrozole and taselisib as a neoadjuvant treatment (before surgery) in patients with hormone receptor-positive, HER2-negative, early stage breast cancer. This study concluded that this treatment...
Read More
In a nutshell This phase 1/2 trial will investigate the safety of OBT076 in patients with advanced breast cancer. The main outcomes will be the frequency of side effects and response to treatment. This trial is recruiting at Columbia University Medical Center, NY, US. The details Breast cancer (BC) is a highly treatable...
Read More
In a nutshell This trial is examining the most beneficial dose of an experimental AE37 vaccine when used with biological therapy pembrolizumab (Keytruda). The main outcomes to be measured are the maximum safest dose of AE37 and objective response rate. This study is recruiting in Illinois and West Virginia, US. The details Triple-negative...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read More
